Cytek Biosciences Reports Strong Preliminary Q4 and Full Year 2025 Revenue

summarizeSummary

Cytek Biosciences announced preliminary unaudited revenue results for Q4 and full year 2025, showing accelerated growth driven by strong performance in services, reagents, and instrument sales.

check_boxKey Events

• Preliminary Q4 2025 Revenue Announced

  Cytek Biosciences expects preliminary unaudited revenue for the fourth quarter ended December 31, 2025, to be approximately $62 million, representing 8% growth compared to Q4 2024 and 19% growth compared to Q3 2025.

• Preliminary Full Year 2025 Revenue Reported

  The company anticipates preliminary unaudited total revenue for the full year 2025 to be approximately $201 million.

• CEO Highlights Growth Acceleration

  Dr. Wenbin Jiang, CEO, noted a 'meaningful acceleration of growth' in Q4, driven by strong performance in Services, Reagents, Asia Pacific instrument revenue, and improved instrument revenue growth in the US and EMEA, including a return to positive growth in EMEA instrument sales.

• Upcoming J.P. Morgan Healthcare Conference Presentation

  Cytek Biosciences is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.

auto_awesomeAnalysis

Cytek Biosciences announced preliminary unaudited revenue results for the fourth quarter and full year 2025, indicating a positive performance trend. The reported acceleration in Q4 growth, particularly in instrument sales in EMEA, suggests improving business momentum. While these results are preliminary and subject to audit, they provide an early, optimistic signal ahead of the full earnings report and the company's presentation at the J.P. Morgan Healthcare Conference. Investors will likely view this as a positive indicator for the company's financial health and operational execution.